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Abstract
Background: Eczema is a chronic, itchy skin condition that can have a large impact on the quality of life of patients and
their families. People with eczema are often keen to try out non-pharmacological therapies like silk therapeutic garments
that could reduce itching or the damage caused by scratching. However, the effectiveness and cost-effectiveness of
these garments in the management of eczema has yet to be proven. The CLOTHES Trial will test the hypothesis that
‘silk therapeutic garments plus standard eczema care’ is superior to ‘standard care alone’ for children with moderate to
severe eczema.
Methods/Design: Parallel group, observer-blind, pragmatic, multi-centre randomised controlled trial of 6 months’
duration.
Three hundred children aged 1 to 15 years with moderate to severe eczema will be randomised (1:1) to receive silk
therapeutic garments plus standard eczema care, or standard eczema care alone. Primary outcome is eczema severity, as
assessed by trained and blinded investigators at 2, 4 and 6 months (using the Eczema Area and Severity Index (EASI)).
Secondary outcomes include: patient-reported eczema symptoms (collected weekly for 6 months to capture long-term
control); global assessment of severity; quality of life of the child, family and main carer; use of standard eczema
treatments (emollients, corticosteroids applied topically, calcineurin inhibitors applied topically and wet wraps); frequency
of infections; and cost-effectiveness. The acceptability and durability of the clothing will also be assessed, as will
adherence to wearing the garments. A nested qualitative study will assess the views of a subset of children wearing the
garments and their parents, and those of healthcare providers and commissioners.
Randomisation uses a computer-generated sequence of permuted blocks of randomly varying size, stratified by
recruiting hospital and child’s age (< 2 years; 2 to 5 years; > 5 years), and concealed using a secure web-based system.
The sequence of treatment allocations will remain concealed until randomisation and data collection are complete.
Recruitment is taking place from November 2013 to May 2015, and the trial will be completed in 2016. Full details of
results will be published in the National Institute for Health Research Journal series.
Trial registration: Current Controlled Trials ISRCTN77261365 (registered 11 November 2013).
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Background
Eczema (synonymously atopic eczema, atopic dermatitis) is
a chronic, inflammatory skin condition that affects around
one in five children and appears to be increasing in preva-
lence worldwide [1]. Whilst most cases of eczema can be
successfully treated with topical medications, many parents
express inconvenience and/or concern in using these
preparations and are keen to explore non-pharmacological
treatment options.
Some types of clothing can cause irritation to the skin,
and current guidelines recommend the use of loose cot-
ton clothing, and the avoidance of wool and other rough
fibres next to the skin [2]. In response to this need, new
clothing products have become available in recent years,
with many marketed as having beneficial effects in the
treatment of eczema. The therapeutic silk garments in-
cluded in this study are available on prescription in the
UK, at a cost ranging from £35.15 to £52.54 for a child’s
bodysuit/top and £24.95 to £32.49 for child’s leggings
[3]. However, the evidence from randomised controlled
trials (RCTs) supporting the use of these garments is
currently limited [4, 5].
Searching the Global Resource of Eczema Trials [6]
(last search date: 19 March 2015), 9 small RCTs assessing
the effects of therapeutic clothing have been published to
date. Two trials investigated silver-coated textiles [7, 8];
one investigated cellulose fibres with seaweed enriched
with silver ions [9]; one investigated an anion textile [10];
two investigated types of ethylene vinyl alcohol fibre [11,
12] and three investigated silk clothing (DermaSilk™,
Espère Healthcare Ltd, Shefford, UK) [13–15].
The 3 silk clothing trials were too small (22, 30 and
22 participants respectively) to provide robust evi-
dence and inform clinical practice. Due to the limited
evidence available, the National Institute for Health
Research Health Technology Assessment Programme
(NIHR HTA) prioritised the need for a large prag-
matic trial to establish whether or not silk therapeutic
clothing is cost-effective in the management of chil-
dren with eczema. This led to a funding call in 2011
with the subsequent commissioning of the CLOTHing
for the relief of Eczema Symptoms Trial (CLOTHES
ID: 11/65/01). The chosen comparator group was
standard eczema care, so that the additional benefits
of silk therapeutic clothing as an adjuvant to standard
care could be assessed.
The CLOTHES Trial has been developed with support
from the UK Dermatology Clinical Trials Network, and
delivered with assistance from the National Institute for
Health Research Comprehensive Local Research Network.
Objectives
Research hypothesis: that silk therapeutic clothing plus stand-
ard eczema care is superior to standard eczema care alone.
The primary objective is to assess whether silk thera-
peutic clothing, when used in addition to standard eczema
care, reduces eczema severity in children with moderate
to severe eczema over a period of 6 months.
Secondary objectives are to i) estimate the ‘within trial’
cost-effectiveness of silk therapeutic clothing from a
National Health Service (NHS), and separately a family,
perspective; ii) to explore parent/guardian and child views
on, and experiences of, using silk garments and factors
that might influence the use of these garments in everyday
life; and iii) to examine prescribers’/commissioners’ views
of the use of silk garments, to inform prescribing practice.
Methods/Design
The CLOTHES Trial is a multi-centre, parallel group,
observer-blind, pragmatic RCT aiming to recruit 300 chil-
dren with moderate to severe eczema. Participants are
randomised to 2 groups using an allocation ratio of 1:1,
and are followed up for a period of 6 months. The primary
outcome is eczema severity measured using a validated
scale by trained and blinded research nurses at baseline
and 2, 4 and 6 months after randomisation.
Participants randomised to therapeutic clothing are fur-
ther randomised (1:1) to receive one of the two brands of
clothing used in the trial (DermaSilk™, Espère Healthcare
Ltd, Shefford, UK or DreamSkin™, DreamSkin Health Ltd,
Hatfield, UK).
At the end of the 6-month RCT, participants in the
standard care control arm are provided with silk gar-
ments so they have the opportunity to try the garments
for themselves, and to encourage retention in the trial.
All participants are followed up for a further 2 months
(observational period).
During the first 6 months of trial recruitment, an in-
ternal pilot was conducted to assess ability to recruit, ad-
herence with the intervention, and retention in the trial.
The criteria for continuation (≥ 50 % recruitment and
retention) were met and the main trial has continued as
planned. Adherence with the trial intervention, quanti-
fied as wearing the trial garments more than 50 % of the
time, was also very high amongst trial participants
(87.5 %) over this period.
Alongside the trial, qualitative methods are being used
to explore barriers and facilitators to the use of the silk
garments amongst participants in the trial (children and
their parent/guardian), healthcare professional prescribers,
and healthcare commissioners. Participants/parents are
invited to take part in interviews/focus groups once their
participation in the main trial has ended (8 months).
Prescribers and commissioners have been identified via
existing professional networks, and structured telephone
interviews conducted.
Flow of participants through the trial is summarised in
Fig. 1.
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Participants, interventions and outcomes
Setting
Recruitment is taking place in five recruiting centres in the
United Kingdom: Queen’s Medical Centre, Nottingham
University Hospitals NHS Trust; Chase Farm Hospital,
Royal Free London NHS Foundation Trust; Addenbrooke’s
Hospital, Cambridge University Hospitals NHS Foundation
Trust; Queen Alexandra Hospital, Portsmouth Hospitals
NHS Trust and St Mary’s Hospital, Isle of Wight NHS
Trust. Sites were chosen on the basis of a proven track rec-
ord of recruiting into previous eczema trials.
Potential participants are identified through secondary
care, primary care and through local advertising (self-
referral).
Eligibility
Inclusion criteria
 Aged 1 to 15 years at baseline
 Diagnosis of moderate or severe eczema. Presence of
eczema is confirmed using the UK Diagnostic
Criteria for Atopic Eczema [16] and eczema severity
judged using the Nottingham Eczema Severity Scale
(NESS) [17]
 Resident within travelling distance of a recruiting
centre
 At least one patch of eczema on the trunk or limbs
 Parent/legal guardian able to give informed consent
and child willing to take part in the trial
Exclusion criteria
 Taken systemic medication (including light therapy)
or steroids taken orally for eczema within the
previous 3 months
 Started a new treatment regimen within the last
month
Expression of interest
Baseline visit – consent, screening & 
randomisation
Standard care
(n=150)
Standard care + silk clothing
(n=150)
DreamSkin™
(n=75)
DermaSilk™
(n=75)
Optional focus groups and individual 
interviews with a subset of children 
and parent / guardians
Outcome assessments 
(clinic visit at 2 months)
Outcome assessments 
(clinic visit at 4 months)
Outcome assessments
(clinic visit at 6 months)
Questionnaire
8 months 
Standard care group provided 
with trial clothing at 6 months
Fig. 1 Trial flowchart
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 Used wet/dry wraps ≥ five times in the last month
 Currently using silk clothing for their eczema and
are unwilling to stop using the clothing during the
trial
 Currently taking part in another clinical trial
Only one child will be enrolled per family.
The decision was taken to exclude children under
1 year as it is often difficult to diagnose atopic eczema in
very young children (as distinct from irritant dermatitis
or seborrheic dermatitis). Also in this age group children
are growing rapidly making it likely that they would
require replacement garments within the 6-month trial
period.
Interventions
Participants are randomised to receive either standard
eczema care plus silk garments, or standard care alone.
Silk garments The medical device under investigation is
a knitted, sericin-free silk therapeutic garment with a CE
mark for use in eczema. Sericin is a protein that coats
the outside of silk fibres and has the potential to cause
allergic reactions. Medical-grade silk (such as silk used
for stitches during operations) has the sericin removed
for this reason.
The two products being used are DermaSilk™ (Espère
Healthcare Ltd, Shefford, UK) and DreamSkin™ (Dream-
Skin Health Ltd, Hatfield, UK), as these were the two
brands of silk garments available on prescription at the
time of trial design. Participants are instructed to wear the
clothing as often as possible during the day and at night.
Participants receive three sets of garments (long-sleeved
vest and leggings, or body suits and leggings depending on
the age of the child). This was thought to be a sufficient
number of garments to allow for continual use between
washes. Washing instructions are provided in line with
manufacturers’ recommendations.
The product is prepared at the trial coordinating
centre by removing branding labels and packed into
blinded, trial-specific packaging. Upon randomisation,
garments are sent directly to participants’ homes from
the coordinating centre, to maintain the blinding of local
site staff. Garments are replaced as required during the
6-month RCT (e.g. because they are worn out or be-
cause the child has grown). Once the randomised part of
the trial is complete at 6 months, garments are not
replaced.
Standard care All participants continue with their
standard eczema care in line with National Institute for
Health and Care Excellence (NICE) guidance [18] in-
cluding emollients, corticosteroids applied topically and
calcineurin inhibitors applied topically. No efforts are
made to intervene in or change a child’s standard ec-
zema care unless the research nurse thinks that the skin
may be infected. If a research nurse suspects infection
they recommend that the participant contacts their nor-
mal medical team for confirmation of infection and sub-
sequent treatment or change to eczema management.
If a child is currently using ‘specialist’ cotton clothing
(e.g. special sleep suits with built-in mittens), the use of
these garments is recorded, but is not grounds for
exclusion.
Adherence Adherence to wearing the garments is col-
lected on weekly questionnaires until 6 months and then
again at the end of the study (8 months). Participants
randomised to standard care plus silk garments have the
option of using a sticker or tick chart to record the days
and nights when they wear the clothing for the first
6 months. This acts as an aide-mémoire for question-
naire completion.
Concomitant medication All participants continue
with their standard eczema care; however, they are asked
not to start any new treatments for their eczema (other
than antibiotics for skin infection) during the period of
the trial. Participants are asked to refrain from using
other prescription clothing and discouraged from rou-
tinely using bandages or wet or dry wrap dressings. Any
change to a child’s treatment regimen, or use of wet/dry
wrapping, is recorded but the child remains in the trial.
Outcomes
Core outcome domains for collection in eczema trials
have been defined as being eczema signs, eczema symp-
toms, quality of life and long-term control of flares [19].
All four of these outcome domains are included in the
CLOTHES Trial.
Primary outcome The primary outcome is eczema sever-
ity measured by the objective Eczema Area and Severity
Index (EASI) [20] assessed by blinded research nurses at
baseline and 2, 4 and 6 months after randomisation.
EASI was chosen as the primary outcome as it is a val-
idated scale that has been recommended as part of the
core outcome set for use in eczema trials [21]. The scale
captures eczema signs (erythema (redness), excoriation
(scratching), oedema/papulation (swelling and fluid in
the skin) and lichenification (thickening of the skin)). It is
suitable for use in capturing eczema severity by independ-
ent observers who are blinded to treatment allocation.
Secondary outcomes
a) Self-reported eczema symptoms, assessed weekly
using the Patient Oriented Eczema measure (POEM)
[22]. By capturing self-reported eczema severity
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every week for the duration of the trial (6-month
RCT), we will capture long-term control of flares as
well as self-reported eczema symptoms. The POEM is
also collected, once, at the end of the observational
period (8 months).
b) Global assessment of the eczema, assessed by
research nurses (Investigator Global
Assessment: IGA) and by participants (Participant
Global Assessment: PGA) at baseline, 2, 4 and
6 months. This outcome is included to aid
interpretation of the trial findings.
c) Three Item Severity scale (TIS) [23] at baseline, 2, 4
and 6 months, assessed by the research nurses and
used to assess eczema severity. Given the
importance of an objective measure to capture
eczema severity in this observer-blind trial, it was
felt that a second validated eczema severity scale
was warranted.
d) Use of eczema treatments: days of use of steroids
applied topically, calcineurin inhibitors applied
topically, emollients and wet/dry wrapping
throughout the trial. This outcome is important for
helping to interpret the trial results if use of the silk
garments results in changes in the frequency of
application of standard eczema treatments (or
changes in potency).
e) Number of skin infections – defined as
patient-reported skin infections that required
antibiotic or antiviral treatment. Silk therapeutic
garments are purported to reduce the incidence
of clinically-relevant skin infections, but it is also
possible that long-term use of the garments could
exacerbate skin infections. This is an important
safety outcome for the trial.
f ) Health-related quality of life at baseline and at
6 months: Dermatitis Family Impact (DFI) [24] will
assess the impact of the child’s health on the whole
family unit, EuroQol Five Dimension Three Levels
(EQ-5D-3 L) will provide a utility measure for the
main carer; Atopic Dermatitis Quality of Life
preference-based index (ADQoL) [25] and Child
Health Utility, nine dimensions (CHU-9D) [26] will
provide eczema-specific and general health utility
scores respectively.
g) Health resource use, along with f ) health-related
quality of life, will inform the within trial cost-
effectiveness analysis.
Durability of the garments, adherence and acceptabil-
ity of use (as assessed by children and parents/carers) is
also assessed.
Tertiary outcomes Additional exploratory analysis will
be conducted based on eczema severity scores in areas
covered by the clothing (body and limbs) compared to
areas uncovered by the clothing (head and neck), in
order to test the theory that gaining eczema control in
one site may reduce a patient’s overall immunological re-
sponse and, therefore, disease activity at distant sites.
Whilst it is assumed that the different brands of cloth-
ing are similar, the effects of receiving different brands
of clothing will be explored.
All tertiary outcomes will be considered exploratory.
Participant timeline
Recruitment will take place from November 2013 to
May 2015. Each participant is enrolled in the study for
8 months in total (6-month RCT, followed by a 2-month
observational period).
Details of the data collection schedule are summarised
(Table 1).
At 8 months, parents/guardians are sent an invite to the
qualitative component of the study, as well as parent and
age-appropriate child information sheets. Patients and
their families may choose to contact the research team to
express interest in participating in the interviews/focus
groups.
Sample size
Three hundred participants provides 90 % power, at the
5 % significance level (2-tailed) to detect a difference of
around 3 points between the groups in mean EASI
scores over 2, 4 and 6 months using a repeated measures
analysis of covariance (ANCOVA), assuming a SD of 13,
a correlation between EASI scores at different time
points of 0.6 and loss to follow-up of 10 %.
Although a 3-point improvement in EASI sounds like
a small change, it represents a clinically meaningful dif-
ference between groups. A small treatment response
could still be worthwhile to the NHS since this non-
pharmacological treatment is assumed to have no ad-
verse effects, and eczema is widely prevalent among the
general population. It is also likely that a relatively small
response on the objective primary outcome will be
reflected in larger, more clinically meaningful treatment
effects in the patient-reported outcomes.
Recruitment
Recruitment is based in five secondary care hospitals.
Recruitment has primarily been from dermatology and
paediatric allergy clinics at the local sites and through
self-referral as the result of direct local advertising (arti-
cles in press, radio and TV interviews, websites and for-
ums). General practice (GP) surgeries and other local
hospitals in the surrounding area are also being used as
Patient Identification Centres (PICS).
If needed, the usual hospital interpreter and translator
services is available to assist with discussion of the trial,
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but the consent forms and information sheets are not
available in other languages.
Assignment of interventions
Randomisation and blinding
The randomisation schedule is based on a computer-
generated pseudo-random code using random permuted
blocks of randomly varying size, created by the Nottingham
Clinical Trials Unit (Nottingham CTU) in accordance with
their standard operating procedure (SOP) and held on a se-
cure University of Nottingham server. Randomisation is
stratified by recruiting hospital and by child’s age: < 2 years;
2 to 5 years; and > 5 years.
Investigators and research nurses access the random-
isation website by means of a remote, Internet-based
randomisation system developed and maintained by the
Nottingham CTU. The sequence of treatment alloca-
tions will be concealed until interventions have all been
assigned and recruitment, data collection, and all other
trial-related assessments are complete.
After each allocation, the Nottingham CTU coordinat-
ing centre is notified so that participants can be in-
formed by letter of their treatment allocation, and
receive their supply of therapeutic clothing if appropri-
ate. Upon entry into the trial, participants in the thera-
peutic clothing arm are further randomly allocated to
one of two therapeutic clothing brands available on pre-
scription in the UK. They are not aware which brand of
clothing they have received. Packaging, labelling and dis-
tribution of clothing is performed by staff at the
Table 1 Timetable of study assessments
RCT Observational
period
Outcomes collected 0 months 2 months 4 months 6 months 8 months
Informed consent for main study √
Informed consent for genetic study (optional) √
Eligibility checks √
Eczema severity (NESS) √
Supply garments √
intervention
√ control
Demographics √
Collect saliva sample (optional) √
Issue diary √ √ √ √
EASI and TIS √ √ √ √
Investigator and Patient Global Assessment (IGA and PGA) √ √ √ √
Topical treatment usage √ √ √
Medication for skin infection √ √ √ √
Use of wet and dry wraps √ √ √ √
On-line questionnaire (weekly) including POEM, topical treatment use and use of
wet and dry wraps
√ √ √
Final on-line questionnaire √
DFI √ √
EQ-5D-3 L of parent √ √
Child utility scales (ADQoL, CHU-9D) √ √
Number of infections √ √ √ √
Serious adverse events √ √ √
NHS and family resource use √ √ & Diary √ & Diary √ & Diary √
Adherence Ques Ques Ques Ques
Durability of clothing √ √
Acceptability (parent and child) √ √
Replace garments if required (intervention group only) √ √
CHU-9D – The Child Health Utility, nine dimensions, DFI Dermatitis Family Impact questionnaire, EASI Eczema Area and Severity Index, EQ-5D-3 L – EuroQol Five
Dimension, Three Levels questionnaire, NESS Nottingham Eczema Severity Scale, POEM Patient Oriented Eczema Measure, Ques=weekly on-line/postal questionnaire,
TIS Three Item Severity scale
Harrison et al. Trials  (2015) 16:390 Page 6 of 12
coordinating centre and sent to participants by post.
Sizes are determined by collection of the participant’s
height at randomisation
Whilst it is not possible to blind participants to their
treatment allocation, efforts have been made to minimise
expectation bias by emphasising in the trial documents
that the evidence supporting the use of therapeutic cloth-
ing for eczema is currently limited, and that we do not yet
know if this clothing offers any benefit over standard care.
The participant-facing study documents also avoid the use
of value-laden terms such as ‘specialist’ or ‘therapeutic’
clothing for the same reason.
Where possible, research nurses remain blinded through-
out the trial: participants are reminded in the study litera-
ture and in their clinic appointment letters not to wear the
clothing when they attend the clinic, or to mention the
clothing in any way when talking to the research nurses. All
questions relating to the acceptability and use of the cloth-
ing are completed by either postal or on-line questionnaire
(according to patient preference), and telephone and Email
contact with participants is made by trial staff from the co-
ordinating centre whenever possible. If the research nurses
become unblinded, this is recorded and will be used to in-
form a sensitivity analysis.
Full details of blinding arrangements are summarised
(Table 2).
Data collection, management and analysis
Data collection and methods to ensure quality and
retention
Data collection and skin assessments are made by re-
search nurses who have been trained in using the EASI
and TIS instruments, and who are blinded to group allo-
cation. The same research nurse assesses the skin at all
time-points for each participant in order to minimise
inter-observer variability.
On-line questionnaires (or paper questionnaires if pre-
ferred) are used to collect self-reported weekly outcomes,
with Email reminders sent on the day the questionnaire is
due to be completed, and again 2 days later if it has not
been completed. Where participants/parents fail to
complete the questionnaire at 6 and 8 months, or do not
complete weekly questionnaires for 3 consecutive weeks,
attempts are made by the coordinating centre to contact
the family for follow-up. This is done via telephone in the
first instance, and followed up with an Email if necessary.
If a response is not received within a week, a paper copy
of the questionnaire is posted to the parent with a reply
paid envelope.
Participants who fail to attend clinic visits at 2 and/or
4 months continue to be invited to subsequent follow-
up visits unless they opt to withdraw from trial follow-
up.
Data collection and retention rates are being moni-
tored by the Trial Management Group (TMG) through-
out the trial.
Data from the qualitative study will be linked with data
from the RCT to provide a rounded assessment of the
impact of wearing silk garments and the patient-
reported factors that may influence this.
Data collection tools are available at www.nottingham
.ac.uk/CLOTHES.
Data management
Clinic data are entered directly into a web-based trial
database at investigator sites by site users with unique
login details. Patient Questionnaires completed at clinic
visits are transcribed by the site nurses directly into the
trial database.
Patient Questionnaires are completed by participants
at home, via an on-line system built and maintained by
the Nottingham CTU. For the few participants who pre-
fer a paper format, paper questionnaires are returned in
a reply paid envelope to the Nottingham CTU for data
entry into the trial database.
Data quality is ensured by database validation checks
which include missing data, out of range values, illogical
entries and invalid responses. Data entered by sites into
the trial database are subject to monitoring and review
by coordinating centre staff, and data queries are raised
as necessary.
Detailed data management processes and procedures
are documented in the CLOTHES Data Management
Plan.
Statistical methods
All analyses will be carried out using Stata/SE 13.1
(StataCorp, College Station, TX, USA), or MLwiN
Table 2 Summary of blinding status
Blinding status Comments
Participants Not blinded Not possible to blind participants, efforts will be made to minimise expectation bias
Research nurses and PI Blinded Participants will be reminded in their clinic appointment letters not to wear the clothing when they
attend the clinic, or to mention the clothing in any way when talking to the research nurses
Trial staff at
Nottingham CTU
Not blinded Will be the main point of contact for participants wishing to contact the research team, will package and
post the clothing to the participants according to the randomisation schedule, and will provide general advice
Statistician Blinded Statistician will finalise the analysis plan prior to revealing the treatment codes
CTU Clinical Trials Unit, PI Principal Investigator
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v2.2. Appropriate descriptive statistics will be used to
compare the randomised arms at baseline. The pri-
mary approach to analysis will be to analyse partici-
pants as randomised (intention-to-treat), regardless of
adherence with allocation, without imputation of
missing outcome data. Estimates of the intervention
effect will be presented with 95 % confidence inter-
vals and exact p values. Regression models will in-
clude the stratification variables site and age.
The primary analysis for the total EASI score will be
performed using a multilevel model, with observations
at 2, 4 and 6 months (level 1) nested within participants
(level 2) and including baseline EASI and the stratifica-
tion variables as covariates. This model will use all the
observed data and makes the assumption that missing
EASI scores are missing at random given the observed
data. The effect of trial clothing on eczema severity
changing over the study period will be investigated by
including an interaction term between treatment group
and time point in the model. If there is no evidence of a
differential effect over time, a single treatment effect will
be reported. If there is evidence of an interaction effect
then the treatment effect at each different time point
will be reported. The assumptions for the multilevel
model will be checked. Appropriate transformations will
be considered if the assumptions are violated.
Sensitivity analyses for the primary outcome will take
into account adherence with allocation and missing out-
come data.
Analyses of secondary outcomes will be conducted
using appropriate multivariable regression models. Dif-
ferences in means for the intervention group compared
to the standard care group will be presented for continu-
ous outcomes and risk differences and relative risks for
binary outcomes.
Adherence with the trial clothing will be summarised
using the proportion of days and nights that the study
clothing was worn. This will be done for participants
where at least half of the weekly questionnaires were
completed. Sensitivity analyses will explore adherence
for all participants by making different assumptions
about clothing wear during periods where the question-
naire was not completed. Durability and acceptability of
use of the garments will be summarised descriptively.
Full details of the planned analyses, including the tertiary
outcomes, will be documented in the Statistical Analysis
Plan which will be finalised prior to release of treatment al-
location codes for analysis. Any changes in the planned
statistical methods will be documented in the trial report
and a copy of the Statistical Analysis Plan will be made
available at www.nottingham.ac.uk/CLOTHES [27].
Planned sub-group analysis Saliva samples are col-
lected for DNA extraction to test for mutations on the
gene encoding for filaggrin (FLG) to inform a planned
sub-group analysis based on presence or absence of loss
of function mutation(s) in FLG.
For the sub-group analysis, study participants will be
tested for up to 6 of the most prevalent FLG loss-of-
function mutations, depending on quality/quantity of
DNA (R501X, 2282del4, R2447X, S3247X, 3702delG and
3673delC) and categorised into 2 groups according to
FLG genotype:
Group 1: FLG wild-type (no mutations) – control
cohort
Group 2: FLG heterozygous (carrying 1 FLG null
mutation) and FLG homozygous or compound
heterozygous (carrying 2 FLG null mutations)
Health economic evaluation The base case will com-
pare the within trial cost-effectiveness of silk clothing
with standard care to standard care alone from an NHS
perspective. A family perspective will be presented sep-
arately. An incremental cost analysis will compare the
mean per patient costs for the intervention to standard
care, measuring resource use such as primary care con-
tacts, medication prescribed, and secondary care contacts.
Health and family resource use data will be recorded by re-
search nurses. The patients will be asked to collect data on
a diary which will serve as an aide-mémoire. Resource use
will be valued for a common price year using published
unit costs (e.g. Curtis and Netten [28], BNF 2015 [3], and
NHS reference costs) and patient reported estimates. The
costs to the NHS and patient will be reported separately as
well as in combination.
The primary measures of effectiveness for the cost-
effectiveness analysis will be the difference in number of
participants who achieved ‘treatment success’ (defined as
those with at least a 50 % improvement in EASI at
6 months compared to baseline). Secondary analyses will
be conducted using continuous data from the EASI
scale; the Dermatitis Family Impact Scale (DFI) [24]; ec-
zema specific utility measure: the Atopic Dermatitis
Quality of Life preference-based index (ADQoL) [25]
and generic measures of health utility as measured using
the EQ-5D-3 L (for the main carer) and the CHU-9D
[26] for children aged 5 and over (parental proxy for 5
and 6 year olds and self-completing for those aged 7 and
over). A cost utility analysis where effectiveness is mea-
sured in terms of the Quality Adjusted Life Years
(QALYs) for child and main carer will be undertaken
(using linear interpolation and area under the curve with
baseline adjustment) [29].
If non-dominance occurs an incremental cost-
effectiveness ratio will be produced. Decision uncertainty
will be illustrated using a cost-effectiveness acceptability
curve. Sensitivity analysis will be undertaken to test the
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robustness of results in the face of any uncertainties or
assumptions made in the analysis.
Analysis of qualitative component Data from the par-
ent/guardian and child focus groups and interviews and
prescriber and commissioner interviews will be analysed
separately. Parent/guardian and child data will be ana-
lysed using a manual process of thematic analysis. Audio
tapes will be transcribed verbatim. Transcripts, notes
and artefacts (as explained by children) will be reviewed
in detail, coding the substance of the data. Theoretical
codes will be added beside each code as a reminder of
any thoughts or questions attached to the codes. As
codes develop they will be compared with the aim of iden-
tifying similarities and differences amongst incidence in
the data. The identified codes will be condensed into
higher levels of abstraction to form categories; these will
be continuously reviewed to ensure that they cover varia-
tions within the data. The final step will be to interpret
the categories so that better understanding is achieved.
Prescriber and commissioner interviews will be analysed
using the five steps of framework analysis.
Monitoring
Data monitoring
Integrity of trial conduct is overseen by a Trial Steering
Committee (TSC), which meets at least once a year and
provides overall supervision of the trial on behalf of the
trial sponsor (University of Nottingham).
The Trial Management Group (TMG) meets more fre-
quently and is responsible for the day-to-day manage-
ment of the trial. Members of the TMG report to the
TSC at their annual meetings.
As adverse events (AEs) related to the clothing are un-
likely, there is no Data Monitoring Committee, and in-
dependent oversight of trial data collection, management
and analysis is undertaken by the TSC.
The chief investigator (CI) has overall responsibility
for the study and is custodian of the data.
Interim analyses
There are no planned interim between-group analyses.
However, progress with recruitment and retention is
monitored monthly by the TMG. If progress is below
target, strategies will be implemented to improve pro-
gress in discussion with the TSC.
Assessment of harm
It is unlikely that silk garments will result in any adverse
effects. As such collection of AEs, beyond those listed as
trial outcomes, is limited to recording serious adverse
events (SAEs).
A worsening of eczema and infected eczema are not
recorded as AEs as these are collected as specific
outcomes for the trial. Hospitalisation due to eczema is
captured as a SAE.
Ethics and dissemination
Research ethics approval
Ethics approval was granted by NHS Health Research
Authority, NRES Committee East Midlands – Nottingham
1, and the respective NHS Research & Development
(R&D) departments for participating sites (Nottingham
University Hospitals NHS Trust; Barnet and Chase Farm
Hospitals NHS Trust, Cambridge University Hospitals
NHS Foundation Trust, Portsmouth Hospitals NHS Trust
and Isle of Wight NHS Trust) prior to start of recruit-
ment. The trial is being conducted in accordance with the
ethical principles that have their origin in the Declaration
of Helsinki, 1996; the principles of Good Clinical Practice,
and the Department of Health Research Governance
Framework for Health and Social care, 2005.
Protocol amendments
The methods described in this protocol reflect the
current protocol (v 3.0 dated 11 February 2014). A sum-
mary of protocol amendments are summarised (Table 3).
All amendments to the protocol and associated paper-
work have been approved by the trial sponsor, research
ethics committee, local R&D departments, and trial funder
prior to implementation.
Consent
Age-appropriate participant information sheets are pro-
vided for parents/guardians and children, and they have
the opportunity to discuss the study before agreeing to
take part. Participants are identified and contacted by
their normal care provider in the first instance. If they
wish to take part they are asked to contact the research
team and provide contact details. Contact details are
stored securely and separately from other trial data. All
other data are anonymised.
The process for obtaining assent and parent/guardian
informed consent is in accordance with the research eth-
ics committee guidance, and Good Clinical Practice
(GCP). The investigator, or their nominee, and the par-
ticipant or other legally authorised representative both
sign and date the Informed Consent Form before the
person can participate in the study. Children are able to
provide assent to participation in the trial if they wish
to. Separate (optional) consent to provide a saliva sample
for genetic testing to inform a planned sub-group ana-
lysis is taken.
No trial-specific procedures are conducted before in-
formed consent has been obtained, and participants are
reminded that they may withdraw from the trial at any
time without it affecting the quality of their care in the
future.
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Confidentiality
Individual participant medical information obtained as a
result of this study is confidential. Participant confidenti-
ality will be ensured using identification code numbers
to correspond to treatment data in the computer files.
Patient identifiable information will be stored in locked
filing cabinets in a secure room.
Medical information may be given to the participant’s
medical team and all appropriate medical personnel re-
sponsible for the participant’s welfare.
Access to data
Data generated as a result of this trial will be available for
inspection on request by the participating physicians, the
University of Nottingham representatives, the research
ethics committee, local R&D departments and the regula-
tory authorities.
Requests for access to the original anonymised dataset
should be made to the CI.
Post-trial care
After completing the study participants will continue to
receive their standard eczema care through the NHS in
accordance with local practice. All participants can keep
the clothing provided during the trial, to wear as little or
as often as they choose. A summary of the trial results
will be provided to parents if they have given consent
for this.
Dissemination policy
Results will be reported in full through the National In-
stitute for Health Research Journal series (open access),
as well as through peer-reviewed journals, patient news-
letters and websites.
Patient and public involvement
Patients and members of the public have been actively
involved in the design and conduct of the CLOTHES
Trial throughout.
Full details of the extent of patient and public involve-
ment, and the impact that this has had on delivery of
the trial, will be reported separately.
Discussion
The CLOTHES Trial is an independent study that has
been prioritised and commissioned by the NIHR in the
United Kingdom. It will provide high-quality evidence to
inform clinical decision-making on the role of silk thera-
peutic garments for the management of eczema in chil-
dren. This pragmatic trial has been designed to reflect
how silk garments might be used in normal clinical
practice, and usual eczema care is allowed alongside use
of the intervention.
This CLOTHES Trial has generated a significant level
of public interest, and commissioners of healthcare are
awaiting the trial results prior to making decisions over
the future availability of silk garments through the NHS.
As a result, it is likely that the results of the CLOTHES
Trial will inform practice swiftly upon completion.
Our nested qualitative study is being used to inform
the development of an implementation plan that is based
on the views of patients, healthcare providers and com-
missioners, and will help to inform interpretation of the
trial results and guide our dissemination plans.
We are grateful to the two companies who have con-
tributed to the study by donating silk garments for use
in this trial, and appreciate their understanding in ensur-
ing that the trial team remain completely independent of
commercial interest throughout the conduct and report-
ing of the study.
Trial status
The CLOTHES Trial is ongoing. It opened to recruit-
ment in November 2013 and aims to complete recruit-
ment in May 2015. Data collection, analysis and write-
up should be completed by the end of 2016.
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